Beyond PD-1 Blockade: Novel Checkpoint Inhibitors.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 553
- By:
- Publication type:
- Article
Works matching IS 08909091 AND DT 2020 AND VI 34 AND IP 12
Results: 11
1
2
Pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor PD-L1 Score.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 548, doi. 10.46883/onc.2020.3412.0548
- By:
- Publication type:
- Article
3
FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 547, doi. 10.46883/onc.2020.3412.0547
- By:
- Publication type:
- Article
4
Tremelimumab, Durvalumab Combo Shows Promise for Certain Patients with Localized Bladder Cancer.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 540
- Publication type:
- Article
5
Lenvatinib in Combination With Pembrolizumab or Everolimus Shows Promise for Advanced RCC.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 539
- Publication type:
- Article
6
Enzalutamide Induces Added Benefit for Patients With Castration-Resistant Prostate Cancer.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 539
- Publication type:
- Article
7
FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Olaparib.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 539
- Publication type:
- Article
8
Harnessing the Breakthroughs in Lung Cancer Treatment: "We still have some challenging issues.".
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 536, doi. 10.46883/onc.2020.3412.0536
- By:
- Publication type:
- Article
9
Recent Advances in Antibody-Drug Conjugates for Lymphoma.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 522
- By:
- Publication type:
- Article
10
Molecular Therapy: Lung Cancer Leads the Way.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 521, doi. 10.46883/onc.2020.3412.0521
- By:
- Publication type:
- Article
11
Optimizing Therapies For Patients With Lung Cancer.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 12, p. 520, doi. 10.46883/onc.2020.3412.0520
- By:
- Publication type:
- Article